RESULTS: Overall, mean age was 64 years, 31% had diabetes, 23% had previous MI and 41% presented with acute coronary syndrome. Compared to pts treated with 1st generation DES, those treated with 2nd generation DES had more diabetes (p<0.01), multivessel disease (p<0.01), and multiple DES implanted (p<0.001), but angiographic success was similar in both groups (>99%). The occurrence curve for ST (ARC) up to 2 years FU with landmark analysis at 1 year is shown in the Figure.

TCT-485
Paclitaxel Prevented the Intimal Proliferation after Percutaneous Coronary Intervention for Patients with Renal Insufficiency
Hideyuki Takamura1, Toshiya Muramatsu2, Reiko Tsukahara1, Yoshiaki Ito1, Hiroshi Ishimori1, Keisuke Hirano1, Masatsugu Nakano2, Motoharu Araki2, Tamon Katō3, Norihiro Kobayashi1, Yasunari Sakamoto1, Shinsuke Mori1, Masakazu Tsutsumi10, Takuro Takami11, Hiroya Takafuj12, Takahiro Yokoda12
1Saiseikai Yokohama-city Eastern Hospital, Yokohama, Japan, 2Saiseikai Yokohama-city Eastern Hospital, Yokohama, Kanagawa, 3Saiseikai Yokohama City Eastern Hospital, Yokohama, Japan, 4Saiseikai Yokohama City Eastern Hospital, Yokohama, Kanagawa, 5Saiseikai Yokohama City Eastern Hospital, Yokohama, Japan, 6Saiseikai Yokohama-city Eastern Hospital, Yokohama, Kanagawa, 7Saiseikai Yokohama-city Eastern Hospital, Yokohama, Japan, 8Saiseikai Yokohama City Eastern Hospital, Yokohama, Kanagawa, 9Saiseikai Yokohama City Eastern Hospital, Yokohama, Japan, 10Saiseikai Yokohama-city Eastern Hospital, Yokohama, Kanagawa, 11Saiseikai Yokohama-city Eastern Hospital, Yokohama, Kanagawa, 12Saiseikai Yokohama-city Eastern Hospital, Yokohama, Japan

Background: In the first generation drug-eluting stent (DES) era, it had reported that clinical outcome of paclitaxel-eluting stent (PES) deployment was better than sirolimus-eluting stent. But clinical outcome of PCI with second generations DES was not established. Our aim was to investigate the clinical outcomes of hemodialysis (HD) patients after PCI with DES.

Methods: In 6298 consecutive cases which underwent PCI with DES between April 2007 and June 2012, 182 consecutive patients (247 lesions) on HD patients were treated with PES (P group: 93 patients, 117 lesions), everolimus-eluting stent (E group: 54 patients, 78 lesions) or biolimus-eluting stent (B group: 35 patients, 52 lesions) implantation and were follow up to 8 months. The primary endpoints were angiographic outcomes and MACE (death, myocardial infarction, CABG, target lesion revascularization: TLR).

Results: Clinical follow up was obtained on all patients. Angiographic follow up was obtained in 201 lesions (81.4%). No significant difference was detected in the baseline demographic, angiographic, and lesion characteristics. In eight month follow-up, the mean values of late lumen loss (P group: 0.5±0.8mm, E group: 0.9±1.1mm, B group: 0.8±0.8mm, p=0.04) in P group was the lowest in these groups. In multivariate analysis, predictors of TLR were diabetes mellitus (OR: 2.7, 95%CI: 1.1-7.0, p=0.025), BES deployment (OR: 3.4, 95%CI: 1.5-7.5, p=0.0027) and product of serum calcium and phosphorus>38 (OR: 3.6, 95%CI: 1.6-8.9, p=0.016).

Conclusions: In PCI with DES for HD patients, second generation DES hasn’t improved clinical outcomes. PES deployment is still usefulness today.

TCT-484
Impact of Second Generation Drug-Eluting Stents on the Occurrence of Late and Very Late Stent Thrombosis – A Subanalysis of the Large, Prospective DESIRE (Drug-Eluting Stent In the Real World) Registry
Ricardo A. Costa1, Lucas P. Damiani2
1Instituto Dante Pazzanese de Cardiologia, Sao Paulo, Brazil, 2Hospital do Coração - Associação do Sanatório Sírio, Sao Paulo, Sao Paulo

Background: Stent thrombosis (ST) has been described as a rare event in current drug-eluting stent (DES) era; however, its occurrence has been associated with relatively high morbitmortality. Our objective was to investigate the impact of second generation DES on the occurrence of ST in daily clinical practice.

Methods: A total of 4,790 pts (7,530 lesions) undergoing elective for emergency PCI solely with DES as a default strategy were enrolled between May/02-Mar/13. Clinical follow-up (FU) was performed at 1, 6 and 12 months and yearly up to 10 years (97.3%). ST was defined according to the ARC definition. Predictors of ST were recent MI (29.9 vs. 15.2%, p<0.01) and target lesion in saphenous vein grafts (7.4 vs. 5.6, p=0.03), early ST was found in 12.6% of cases (14/111) and independent predictors were recent MI (>97%), ST-free up to 10 years FU (Kaplan-Meier estimate). Compared to those without ST, pts with ST had a trend towards more diabetes (36 vs. 30.5%, p=0.05) and clinical presentation of recent MI (24% vs. 15%, p=0.04), moderate/severe lesion calcification (36.1 vs. 26.8%, p=0.01), poor left ventricle ejection fraction (<30%) (18.2 vs. 2%, p=0.02), multiple DES implanted (56.6 vs. 46.1%, p=0.03) and residual stenosis as assessed by QCA (5 vs. 3.7%, p=0.001). In the multivariate model, independent predictors of ST were recent MI (HR: 2.6, 95% CI 1.5-4.6, p=0.001), recent MI (30 days) (HR 1.89, 95% CI 1.28-2.80, p=0.002), clinical presentation of recent MI (HR 2.21, 95% CI 1.29-3.78, p=0.004), and residual stenosis (HR 1.03 per % with 95% CI 1.00-1.05, p=0.03). Early ST was found in 12.6% of cases (14/111) and independent predictors for this event were diabetes (OR 2.45, p=0.01) and recent MI (<72 hours) (OR 2.6 vs. 1.1, p=0.001).

Conclusions: Compared to 1st generation DES, the use of 2nd generation DES was associated with a non-significant trend towards less occurrence of ST up to 2 years FU, given that there were no very late ST found with 2nd generation DES.